Star OUTiCO, a market-leading provider of outsourced digitally enabled commercial services to the pharmaceutical industry and part of the global Uniphar Group, has launched a new brand identity to communicate to the market the key capabilities and strengths of the combined entity.
The two businesses have been working closely as part of the Uniphar Group’s Clinical & Commercial Division since 2017 specifically to help pharmaceutical and healthcare companies make a commercial impact, adapt to a world that is changing at an accelerated pace, (more so given the impact of COVID-19), and ensure clinicians and patients enjoy better outcomes.
Star Medical was established in 2002 and built a sterling reputation as a recruiter for pharmaceutical sales, marketing, medical devices and market access roles at all levels. Acquired by the Uniphar Group in 2015, Star has gone on to be the leading provider of insight-driven commercial sales solutions for the industry.
OUTiCO, founded in 2010, was the first multi-channel sales company communicating with Health Care Professionals via their preferred sales channel. In a fast-changing commercial environment, this multi-channel approach to brand engagement has allowed OUTiCO to exceed client expectations, prove commercial outcomes and lead the way in this space.
The Group brought OUTiCO into the Uniphar fold to complement Star Medical, with the two businesses together offering the market a digitally enabled comprehensive outsourced sales service proposition, to boost clients’ brand engagement at any and every stage of the commercial lifecycle.
The new Star OUTiCO brand was previewed to team members on 14 September before being unveiled to the market and broader public on 16 September. It has invested heavily in its digital capabilities, with its own in-house experts designing and constructing the proprietary AXiOM platform to gather real-world programme data from multiple sources.
Graham McIntosh, Managing Director, Uniphar Commercial and Clinical Division, said of the launch of the new brand: “It has been an exciting time for everyone since our integration and the formalisation of our combined identity cements the many synergies we have already seen emerge, to the benefit of both our internal operations and the sales impact we make for our clients.
“COVID-19 has shown that the pharmaceutical industry can embrace new technologies very quickly. Before and during COVID-19 our digitally enabled sales approach has helped our clients make a commercial impact and we’re excited to help our partners further grasp the opportunities presented in such a rapidly evolving healthcare environment”.
“There will be winners and losers, so it is down to us to ensure our current and future partners are equipped with the right digitally enabled sales solutions, not only to deliver an impact but to ensure that, rather than a one-off occurrence, impact is a sustained process.”